Coronavirus Peptides

Mimotopes is using up-to-the-minute current information to produce peptides of the highest quality and relevancy for coronavirusresearchers worldwide. 

While a lot of global infrastructure has been shut down, our laboratory is still busy designing and synthesising custom SARS-CoV-2 peptidesWith an appreciation for all the different active avenues of Covid19 research including antigen specific T-cell stimulation and immune monitoring, we’re producing different products to match with the spectrum of research needs.

We have been supplying peptide libraries, peptide pools, individually synthesised peptides, inhibition peptides, and custom made orders, fast tracked for coronavirus research.

Effective Research Tools

Custom peptides are long established tools in vaccine development, drug development, and research into immunotherapies. With rapid synthesis and fast results, coronavirus peptides are effective in antibody screening, antigen discovery, B and T cell epitope mapping, disease screening, and T-cell assays. There are as many potential applications as there are researchers.

Our customers are accelerating their research into covid19 immunity and disease with the essential aid of SARS-CoV-2 peptides

Better Quality Peptides

The minimum purity for each of our coronavirus peptides is over 70%.Some researchers can require higher purities and greater quantities for more specific tests such as detailed explorations of cellular immune response. Our peptide quality is assured across the full range of custom options.

The Mimotopes team has been hard at work synthesising these high quality custom peptides for the major SARS-CoV-2 proteins. These are often modified for the needs of the researcher, such as with biotin labeling. 

Our PepSet™ Peptide Libraries have been used in disease research for decades. Reliable peptide products and convenient specialist services are available online at the click of a button.

Visit our website now to ask about the range of peptides we have available for SARS-CoV-2 research.

Contact us today for a quote 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

✉ useast@mimotopes.com
    uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Breaking the BarrierGo to article: In this issueGo to article: NSFGo to article: ContentsGo to article: AlmacGo to article: NewsGo to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gilead’s remdesivir a candidate for US government stockpiling or bulk buying in Go to article: Covid-19’s impact on trial PROs, other endpoints can be addressed via data stratification, sensitivity analysisGo to article: ILC Dover Go to article: Vitamin D affects Covid-19 mortalityGo to article: Clinical trial disruption due to Covid-19 has begun to slowGo to article: Covid-19 boosts big bio/pharma drug sales but Regeneron may be falling shortGo to article: MimotopesGo to article: The pharma industry briefingGo to article: Charting the ups and downs of the World Health OrganizationGo to article: Road to RECOVERY: a deep dive into the world’s largest Covid-19 drug trialGo to article: Salvaging clinical trials in the time of Covid-19Go to article: Intellectual property in the time of Covid-19Go to article: Molnár-Institute Company InsightGo to article: Molnar-InstituteGo to article: A plight for sore eyes: the latest developments in seasonal allergy treatmentGo to article: How research groups are tackling the problem of biologic drug delivery Go to article: Breaking the blood-brain barrier: neurology’s greatest challengeGo to article: Timeline: charting the history of immunotherapy, cancer treatment's fourth pillarGo to article: Creating a sure data footing for AIGo to article: Koehler eClinicalGo to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue